MTOR and hepatocellular carcinoma: Overall, although some clinical trials have shown that mTOR inhibitors can provide a survival benefit in patients with advanced HCC, especially when they were intolerant to sorafenib (a standard first-line therapy for advanced HCC), not all trials have demonstrated a significant improvement in overall survival with the treatment of an mTOR inhibitor.